Novartis's Entresto Receives the US FDA's Advisory Committee Recommendation to Treat Patients with HFpEF
Shots:
- The US FDA’s CRDAC voted 12 to 1 supporting the use of Entresto (sacubitril/valsartan) in the treatment of patients with HFpEF
- The decision was based on efficacy & safety analyses- including findings from a pre-specified subgroup analysis of PARAGON-HF (P-III study in HFpEF) and additional evidence from PARAMOUNT (P-II trial in HFpEF)- as well as PARADIGM-HF (P-III trial in HFrEF)
- Entresto (sacubitril/valsartan) is a prescription medicine used to reduce the risk of CV death & heart failure hospitalization in people with long-lasting heart failure
Ref: PRNewswire | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com